GYRE Q3 2021 Earnings Call Summary

1Key Financial Results and Metrics

Cash position as of September 30, 2021: $64.5 million.

Anticipated cash burn reduction of approximately 40% due to halting MarzAA development, bringing quarterly burn down from over $20 million to around $13 million.

2Strategic Updates and Business Highlights

Catalyst Biosciences announced a strategic pivot to discontinue the clinical development of MarzAA and focus on its complement programs and protease medicines platform.

The decision to halt MarzAA was influenced by slow enrollment in clinical trials, logistical challenges from the pandemic, and increased competition for study subjects.

The company plans to report data from the ongoing MAA-304 (Crimson-1) trial, which has shown successful treatment of bleeds with no adverse events reported.

The complement portfolio includes candidates CB 4332 (targeting complement factor I deficiency) and CB 2782-PEG (licensed to Biogen for dry AMD), with plans to submit an IND for CB 4332 in 2022.

3Forward Guidance and Outlook

The company aims to initiate the first-in-human trial for CB 4332 in 2022 following the completion of the ConFIdence natural history study.

The complement market is viewed as a significant growth opportunity, with plans to continue developing candidates from their protease platform.

4Bad News, Challenges, or Points of Concern

The decision to halt MarzAA development reflects challenges in enrollment and financial viability, raising concerns about the company's ability to sustain late-stage programs without partnerships.

The timeline for completing the MAA-304 study has been pushed to late 2023, which may impact investor confidence and future funding opportunities.

The company faces competitive pressures in the hemophilia space, particularly with the availability of alternative therapies.

5Notable Q&A Insights

Management confirmed that the decision to halt MarzAA was primarily driven by enrollment challenges and the long timeline for trial completion.

The company is actively seeking partnerships for the MarzAA and DalcA portfolios, though specific outreach details were not disclosed.

Confidence in the immunogenicity profile of CB 4332 was expressed, with ongoing assessments to ensure safety before clinical trials.

The complement factor I deficiency is characterized as an ultra-orphan indication, with ongoing efforts to identify and enroll patients for trials. Overall, Catalyst Biosciences is shifting its focus towards its complement and protease platforms, aiming for long-term value creation while addressing immediate financial and operational challenges.